Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016–2019)

References

• Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114–131.
   PubMed Web of Science ®Google Scholar
• Medina M, Wandosell F. Deconstructing GSK-3: the fine regulation of its activity. Int J Alzheimers Dis. 2011;2011:479249.
   PubMedGoogle Scholar
• Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem. 1980;107(2):519–527.
   PubMedGoogle Scholar
• Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci. 2010;11(8):539–551.
   PubMed Web of Science ®Google Scholar
• Phukan S, Babu VS, Kannoji A, et al. GSK3beta: role in therapeutic landscape and development of modulators. BrJ Pharmacol. 2010;160(1):1–19.
   PubMed Web of Science ®Google Scholar
• Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000;406(6791):86–90.
   PubMed Web of Science ®Google Scholar
• Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 2004;25(9):471–480.
   PubMed Web of Science ®Google Scholar
• Maqbool M, Mobashir M, Hoda N. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer’s disease. Eur J Med Chem. 2016;107:63–81.
   PubMed Web of Science ®Google Scholar
• Giese KP. GSK-3: a key player in neurodegeneration and memory. IUBMB Life. 2009;61(5):516–521.
   PubMed Web of Science ®Google Scholar
• Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets. 2006;7(11):1435–1441.
   PubMed Web of Science ®Google Scholar
• Lal H, Ahmad F, Woodgett J, et al. The GSK-3 family as therapeutic target for myocardial diseases. Circ Res. 2015;116(1):138–149.
   PubMed Web of Science ®Google Scholar
• Lin J, Song T, Li C, et al. GSK-3beta in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Biochim Biophys Acta Mol Cell Res. 2020;1867(5):118659–118665.
   PubMed Web of Science ®Google Scholar
• Taylor A, Rudd CE. Small molecule inhibition of glycogen synthase kinase-3 in cancer immunotherapy. Adv Exp Med Biol. 2019;1164:225–233.
   PubMed Web of Science ®Google Scholar
• Ko R, Lee SY. Glycogen synthase kinase 3beta in Toll-like receptor signaling. BMB Rep. 2016;49(6):305–310.
   PubMed Web of Science ®Google Scholar
• Hoffmeister L, Diekmann M, Brand K, et al. GSK3: A kinase balancing promotion and resolution of inflammation. Cells. 2020;9:820–830.
   PubMed Web of Science ®Google Scholar
• Duthie A, van Aalten L, MacDonald C, et al. Recruitment, retainment, and biomarkers of response, a pilot trial of lithium in humans with mild cognitive impairment. Front Mol Neurosci. 2019;12:163–179.
   PubMed Web of Science ®Google Scholar
• Lovestone S, Boada M, Dubois B, et al. A phase II trial of tideglusib in Alzheimer’s disease. J Alzheimers Dis. 2015;45(1):75–88.
   PubMed Web of Science ®Google Scholar
• Palomo V, Martinez A. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014–2015). Expert Opin Ther Pat. 2017;27(6):657–666.
   PubMed Web of Science ®Google Scholar
• Anagnostou E Tideglusib vs. placebo in the treatment of adolescents with autism spectrum disorders (TIDE). Available from: https://clinicaltrials.gov/ct2/show/NCT02586935
   Google Scholar
• de Vries Schultink AH, Suleiman AA, Schellens JH, et al. Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. Eur J Clin Pharmacol. 2016;72(6):645–653.
   PubMed Web of Science ®Google Scholar
• Eldar-Finkelman H, Martinez A. GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci. 2011;4:32–50.
   PubMed Web of Science ®Google Scholar
• Pandey MK, DeGrado TR. Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging. Theranostics. 2016;6(4):571–593.
   PubMed Web of Science ®Google Scholar
• Kuroki H, Anraku T, Kazama A, et al. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019;9(1):19977–19986.
   PubMedGoogle Scholar
• Li L, Shao X, Cole EL, et al. Synthesis and initial in vivo studies with [(11)C]SB-216763: the first radiolabeled brain penetrative inhibitor of GSK-3. ACS Med Chem Lett. 2015;6(5):548–552.
   PubMed Web of Science ®Google Scholar
• Liang SH, Chen JM, Normandin MD, et al. Discovery of a highly selective glycogen synthase kinase-3 inhibitor (PF-04802367) that modulates tau phosphorylation in the brain: translation for PET neuroimaging. Angew Chem Int Ed Engl. 2016;55(33):9601–9605.
   PubMed Web of Science ®Google Scholar
• Bernard-Gauthier V, Mossine AV, Knight A, et al. Structural basis for achieving GSK-3beta inhibition with high potency, selectivity, and brain exposure for positron emission tomography imaging and drug discovery. J Med Chem. 2019;62(21):9600–9617.
   PubMed Web of Science ®Google Scholar
• Esfandiari F, Fathi A, Gourabi H, et al. Glycogen synthase kinase-3 inhibition promotes proliferation and neuronal differentiation of human-induced pluripotent stem cell-derived neural progenitors. Stem Cells Dev. 2012;21(17):3233–3243.
   PubMed Web of Science ®Google Scholar
• Welham MJ, Kingham E, Sanchez-Ripoll Y, et al. Controlling embryonic stem cell proliferation and pluripotency: the role of PI3K- and GSK-3-dependent signalling. Biochem Soc Trans. 2011;39(2):674–678.
   PubMedGoogle Scholar
• Tucker TA, Idell S. Glycogen synthase kinase-3β inhibition with 9-ING-41 attenuates the progression of pulmonary fibrosis. Sci Rep. 2019;9:18925–18938.
   PubMed Web of Science ®Google Scholar
• Barratt SL, Creamer A, Hayton C, et al. Idiopathic pulmonary fibrosis (IPF): an overview. J Clin Med. 2018;7(8):201–222.
   Web of Science ®Google Scholar
• Fujimoto H, Kobayashi T, Azuma A. Idiopathic pulmonary fibrosis: treatment and prognosis. Clin. Med. Insights Circ Respir Pulm Med. 2015;9(Suppl 1):179–185.
   PubMedGoogle Scholar
• Ugolkov AV, Bondarenko GI, Dubrovskyi O, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018;29(8):717–724.
   PubMed Web of Science ®Google Scholar
• Boren J, Shryock G, Fergis A, et al. Inhibition of glycogen synthase kinase 3beta blocks mesomesenchymal transition and attenuates streptococcus pneumonia-mediated pleural injury in mice. Am J Pathol. 2017;187(11):2461–2472.
   PubMed Web of Science ®Google Scholar
• University SN Application of glycyrrhizic acid to prepare drugs for promotign medullary sheath regeneration to restrain neurogenic inflammation; 2018. (CN109528738).
   Google Scholar
• Jia YX, Li JR, Mao CY, et al. Glycyrrhizin improves p75NTR-associated sciatic nerve regeneration in a BALB/c mouse model. Exp Ther Med. 2014;7(5):1141–1146.
   PubMed Web of Science ®Google Scholar
• Kao TC, Shyu MH, Yen GC. Glycyrrhizic acid and 18beta-glycyrrhetinic acid inhibit inflammation via PI3K/Akt/GSK3beta signaling and glucocorticoid receptor activation. J Agric Food Chem. 2010;58(15):8623–8629.
   PubMed Web of Science ®Google Scholar
• Sato N, Meijer L, Skaltsounis L, et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004;10(1):55–63.
   PubMed Web of Science ®Google Scholar
• Neves VC, Babb R, Chandrasekaran D, et al. Promotion of natural tooth repair by small molecule GSK3 antagonists. Sci Rep. 2017;7:39654–39661.
   PubMed Web of Science ®Google Scholar
• Sharpe PT Dental treatment; 2018. (WO2018073599A1).
   Google Scholar
• Reichman S, Terray A, Slembrouck A, et al. From confluent human iPS cells to self-forming neural retina and retinal pigmented epithelium. Proc Natl Acad Sci U S A. 2014;111(23):8518–8523.
   PubMed Web of Science ®Google Scholar
• Reichman SGO, Sahel J-A Compositions and methods for efficent amplification of retinal progenitors cells; 2019. (WO2019170766A1).
   Google Scholar
• Ni W, Zeng S, Li W, et al. Wnt activation followed by Notch inhibition promotes mitotic hair cell regeneration in the postnatal mouse cochlea. Oncotarget. 2016;7(41):66754–66768.
   PubMedGoogle Scholar
• Roccio M, Hahnewald S, Perny M, et al. Cell cycle reactivation of cochlear progenitor cells in neonatal FUCCI mice by a GSK3 small molecule inhibitor. Sci Rep. 2015;5:17886–17897.
   PubMed Web of Science ®Google Scholar
• Loose CMW, Middletown H, Jirousek MR. Solubilized compositions for controlled proliferation of stem cells/generating inner ear hair cells using GSK3 inhibitors: III; 2016. (US10016507B2).
   Google Scholar
• Loose CMW, Middletown H, Jirousek MR. Solubilized compositions for controlled proliferation of stem cells/generating inner ear hair cells using GSK3 inhibitors: II; 2017. (US2017/0252329A1).
   Google Scholar
• Loose CMW, Middletown H, Jirousek MR Solubilized compositions for controlled proliferation of stem cells/generating inner ear hair cells using GSK3 inhibitors: IV; 2017. (US20170252450A1).
   Google Scholar
• Loose CMW, Middletown H, Jirousek MR Solubilized compositions for controlled proliferation of stem cells/generating inner ear hair cells using GSK3 inhibitors:I; 2019. (US20190201398).
   Google Scholar
• Toyoda T, Mae S, Tanaka H, et al. Cell aggregation optimizes the differentiation of human ESCs and iPSCs into pancreatic bud-like progenitor cells. Stem Cell Res. 2015;14(2):185–197.
   PubMed Web of Science ®Google Scholar
• Bazan NMF A modified cell culture medium and uses thereof; 2018. (WO2018187428).
   Google Scholar
• Corporation K Method for producing insulin-producing cells; 2019. (WO/2019/151098).
   Google Scholar
• Ochiya TKT Method for producing hepatic stem/precursor cells from mature hepatic cells using low-molecular-weight compound; 2017. (US2019/010464A1).
   Google Scholar
• Fuchs C, Fustini N, Trazzi S, et al. Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice. Eur J Neurosci. 2018;47(9):1054–1066.
   PubMed Web of Science ®Google Scholar
• Ciani E, Fuchs C Treatment of cdkl5 disorders with gsk-3 inhibitor Tideglusib; 2017. (WO-2017153834-A1).
   Google Scholar
• Gramatica A Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor; 2018. (WO/2018/226721).
   Google Scholar
• Balasubramaniam M, Pandhare J, Dash C. Immune control of HIV. J Life Sci (Westlake Village). 2019;1(1):4–37.
   PubMedGoogle Scholar
• Vanhamel J, Bruggemans A, Debyser Z. Establishment of latent HIV-1 reservoirs: what do we really know? J Virus Erad. 2019;5(1):3–9.
   PubMed Web of Science ®Google Scholar
• Ling TZY, Hanse Y, Zhangzhan X, et al. Application of GSK3 inhibitor in preparing a drug to treat niemann-pick disease type C; 2018. (WO/2018/064922).
   Google Scholar
• Geberhiwot T, Moro A, Dardis A, et al. International niemann-pick disease R., consensus clinical management guidelines for niemann-pick disease type C. Orphanet J Rare Dis. 2018;13(1):50.
   PubMedGoogle Scholar
• Wagner FF, Bishop JA, Gale JP, et al. Inhibitors of glycogen synthase kinase 3 with exquisite kinome-wide selectivity and their functional effects. ACS Chem Biol. 2016;11(7):1952–1963.
   PubMed Web of Science ®Google Scholar
• Xu L, Zheng J, Margittai M, et al., How does hyperphopsphorylation promote tau aggregation and modulate filament structure and stability? ACS Chem Neurosci. 7(5):565–575. 2016.
   PubMed Web of Science ®Google Scholar
• Song Y, Kim HD, Lee MK, et al. Maysin and its flavonoid derivative from centipedegrass attenuates amyloid plaques by inducting humoral immune response with th2 skewed cytokine response in the Tg (APPswe, PS1dE9) Alzheimer’s mouse model. PLoS One. 2017;12(1):e0169509.
   PubMed Web of Science ®Google Scholar
• Li QXL. Z. GSK-3B inhibitors and use thereof in methods of treatment; 2019. (WO/2019/108877).
   Google Scholar
• Wagner F, Weiwer M, Campbell AJ, et al. Tricyclic compounds as clycogen synthase kinase (GSK3) inhibitors and uses thereof; 2018. (WO/2018/187630).
   Google Scholar
• Lauretti E, Dincer O, Pratico D. Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res. 2020;1867(5):118664–118671.
   PubMed Web of Science ®Google Scholar
• Alisi MA, Cazzola N, Dragone P, et al. 1H-indazole-3-carboxamide compunds as glycogen synthase kinase 3 beta inhibitors; 2017. (WO2013124158A1).
   Google Scholar
• O´Flaherty LTJ, Seckl MJ, Pardo OE. Therapy; 2018. (WO/2018/083483).
   Google Scholar
• Mathuram TL, Reece LM, Cherian KM. GSK-3 inhibitors: a double-edged sword? - an update on tideglusib. Drug Res (Stuttg). 2018;68(8):436–443.
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F. Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol. 2013;86(2):191–199.
   PubMed Web of Science ®Google Scholar
• Avrahami L, Licht-Murava A, Eisenstein M, et al. GSK-3 inhibition: achieving moderate efficacy with high selectivity. Biochim Biophys Acta. 2013;1834(7):1410–1414.
   PubMed Web of Science ®Google Scholar
• Palomo V, Perez DI, Perez C, et al. 5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. J Med Chem. 2012;55(4):1645–1661.
   PubMed Web of Science ®Google Scholar
• Bidon-Chanal A, Fuertes A, Alonso D, et al. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. Eur J Med Chem. 2013;60:479–489.
   PubMed Web of Science ®Google Scholar
• Palomo V, Soteras I, Perez DI, et al. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J Med Chem. 2011;54(24):8461–8470.
   PubMed Web of Science ®Google Scholar
• Chen YY, Chen G, Fan Z, et al. GSK3beta and endoplasmic reticulum stress mediate rotenone-induced death of SK-N-MC neuroblastoma cells. Biochem Pharmacol. 2008;76(1):128–138.
   PubMed Web of Science ®Google Scholar
• Mancinelli R, Carpino G, Petrungaro S, et al. Multifaceted roles of GSK-3 in cancer and autophagy-related diseases. Oxid Med Cell Longevity. 2017;2017:4629495–4629509.
   PubMed Web of Science ®Google Scholar
• Singh AP, Umbarkar P, Guo Y, et al. Inhibition of GSK-3 to induce cardiomyocyte proliferation: a recipe for in situ cardiac regeneration. Cardiovasc Res. 2019;115(1):20–30.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Katz SC, Sengupta S, et al. Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells. Cancer Lett. 2018;433:131–139.
   PubMed Web of Science ®Google Scholar